1x10^8 CFU/day (the dose that outperformed both placebo and higher 1x10^10 doses in the Whorwell 2006 dose-ranging trial); typically one capsule once daily, taken for at least 4-8 weeks; benefit is lost after discontinuation, so continued daily use is needed.
Active Compounds
Bifidobacterium longum subsp. longum 35624 (reclassified from B. infantis 35624)Branded as Align (US), Alflorex (EU/PrecisionBiotics), and BifantisSingle-strain encapsulated probioticTrademarked as 35624
Safety & Cautions
⚠
Well tolerated in trials; adverse events were comparable to placebo, with rare mild nausea reported. No serious adverse events in IBS or pediatric studies; 89% of participants rated tolerability good to very good. As with any live probiotic, exercise caution in critically ill, immunocompromised patients, or those with central venous catheters, where translocation/bacteremia is a theoretical concern; bifidobacteremia is exceedingly rare. Check with your doctor or pharmacist before combining it with any medicine.
Common questions about Bifidobacterium infantis 35624
What is Bifidobacterium infantis 35624 used for?
Bifidobacterium infantis 35624 is most often taken for easing IBS symptoms. The flagship IBS strain — immune-modulating Bifidobacterium with landmark trial evidence. Benefits studied: Eases overall IBS symptoms (abdominal pain, bloating, bowel dysfunction) at 1x10^8 CFU/day in double-blind RCTs; Reduces abdominal pain/discomfort versus placebo across most treatment weeks (O'Mahony 2005); Improves global IBS symptom assessment by >20% over placebo (Whorwell 2006); Reduces functional abdominal bloating/distention.
Does Bifidobacterium infantis 35624 work — what does the evidence say?
Moderate evidence. Several controlled trials; effects real but modest or context-dependent. Bifidobacterium 35624 (originally B. infantis 35624, reclassified after genome sequencing as B. longum subsp. longum 35624; sold as Align/Bifantis) is the best-studied single strain for irritable bowel syndrome (IBS). Two landmark double-blind RCTs (O'Mahony 2005, n=77; Whorwell 2006, n=362 women) found that 1x10^8 CFU/day significantly reduced abdominal pain, bloating, bowel dysfunction and global symptoms versus placebo, with the benefit linked to normalization of a pro-inflammatory IL-10/IL-12 cytokine ratio. Evidence is graded moderate rather than strong because a 2017 meta-analysis found the pooled single-strain effect on individual symptoms was not statistically significant, even though more recent open-label and pediatric studies report large IBS-SSS reductions. Effects are strain-specific and should not be generalized to other bifidobacteria.
What is the typical dose of Bifidobacterium infantis 35624?
1x10^8 CFU/day (the dose that outperformed both placebo and higher 1x10^10 doses in the Whorwell 2006 dose-ranging trial); typically one capsule once daily, taken for at least 4-8 weeks; benefit is lost after discontinuation, so continued daily use is needed.
Is Bifidobacterium infantis 35624 safe? Any cautions or side effects?
Well tolerated in trials; adverse events were comparable to placebo, with rare mild nausea reported. No serious adverse events in IBS or pediatric studies; 89% of participants rated tolerability good to very good. As with any live probiotic, exercise caution in critically ill, immunocompromised patients, or those with central venous catheters, where translocation/bacteremia is a theoretical concern; bifidobacteremia is exceedingly rare.
How many studies support Bifidobacterium infantis 35624?
NutriDex cites 12 sources for Bifidobacterium infantis 35624, graded "Moderate".
Cite this page
APA
Peh, D. (2026). Bifidobacterium infantis 35624 (Bifidobacterium longum subsp. infantis 35624): Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 13 Nov 2026, from https://nutridex.info/s/b-infantis-35624
BibTeX
@misc{nutridex_b_infantis_35624,
author = {Peh, Daryl},
title = {Bifidobacterium infantis 35624 (Bifidobacterium longum subsp. infantis 35624): Benefits, Dosage, Side Effects \& Evidence},
year = {2026},
howpublished = {NutriDex --- The Supplement Research Compendium},
url = {https://nutridex.info/s/b-infantis-35624},
note = {Physician-reviewed. Accessed 2026-11-13}
}
For medical claims, cite the primary studies linked above.